Alpha-1 antitrypsin (AAT) deficiency
Alpha-1 antitrypsin (AAT) deficiency
批准号:
10469247
负责人:
James Inglese
金额:
$6.54万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdultAgeAlzheimer&aposs DiseaseApoptosisAutophagocytosisBiological AssayBiological ModelsCell modelChildCystic FibrosisDevelopmentDiseaseEndoplasmic ReticulumFinancial SupportGenesGeneticGenetic DiseasesHepatocyteImpairmentInheritedLeadLiver diseasesLung diseasesMeasuresMethodsMolecular ConformationNon-Insulin-Dependent Diabetes MellitusParentsPhenotypePolymersProtein ConformationProteinsProteolysisRoleStressSystemTechnologyTestingalpha 1-Antitrypsinalpha 1-Antitrypsin Deficiencyassay developmentdesigninnovationliver developmentloss of functionmonomermulticatalytic endopeptidase complexmutantnovelnovel therapeutic interventionresearch and developmentscreeningsmall molecule librariestherapeutic developmenttrafficking
中文摘要
检测开发和筛选技术(ADST)旨在通过研究和开发创新的检测(测试)设计和化学库筛选方法来推动治疗开发。构象疾病是由新合成的蛋白质错误折叠和促进蛋白质构象成熟、细胞内转运和蛋白质降解的系统被颠覆而引起的一组疾病。这些疾病包括阿尔茨海默病、囊性纤维化、2型糖尿病和阿尔法-1抗胰蛋白酶(AAT)缺乏症。AAT是一种遗传疾病,通过父母的基因遗传给他们的孩子。携带Alpha-1基因的人收到了两个异常的Alpha-1抗胰蛋白酶基因。后一种疾病是由肝细胞内质网中遗传突变的AAT单体的错误折叠引起的。错误折叠的单体可被蛋白酶体降解,但可形成有毒的聚合物,可通过自噬移除,而应激肝细胞已知会发生凋亡。AAT的分泌受损可导致成人的严重肺部疾病(功能丧失),而肝细胞中有毒聚合物的积聚可导致任何年龄的肝病(毒性功能的获得)。重要的是,有广泛的表型变异,暗示了遗传和/或环境修饰物的作用。在Alpha-1项目(TAP)的初步资金支持下,我们设计了新的生物检测和技术,以启动对AAT缺乏症的新的治疗干预措施的发现和开发,这可能为治疗其他构象障碍提供一般策略。
英文摘要
Assay Development & Screening Technology (ADST) is designed to advance therapeutic development through research and development of innovative assay (test) designs and chemical library screening methods. Conformational diseases are a group of disorders caused by the misfolding of newly synthesized proteins and subversion of systems that facilitate protein conformational maturation, intracellular trafficking, and proteolysis. They include Alzheimers Disease, Cystic Fibrosis, Type 2 Diabetes, and Alpha-1 antitrypsin (AAT) deficiency. AAT is a genetic condition that is passed from parents to their children through their genes. People with Alpha-1 have received two abnormal alpha-1 antitrypsin genes. The latter disorder is caused by the misfolding of an inherited mutant AAT monomer in the endoplasmic reticulum of hepatocytes. The misfolded monomer is degraded by proteasomes, but can form toxic polymers that are removed by autophagy, and stressed hepatocytes are known to undergo apoptosis. The impaired secretion of AAT can result in serious lung disease in adults (loss of function), whereas the accumulation of toxic polymers in hepatocytes can lead to the development of liver disease at any age (gain of toxic function). Importantly there is extensive phenotypic variability, implicating roles for genetic and/or environmental modifiers. With initial financial support from The Alpha-1 Project (TAP) we designed novel bioassays and technologies to initiate discovery and development of new therapeutic interventions for AAT deficiency, which may provide general strategies to treat additional conformational disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Juvenile Myositis
-
批准号:9770482
-
项目类别:
-
资助金额:$18.63万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Juvenile Myositis
-
批准号:10007538
-
项目类别:
-
资助金额:$17.05万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Juvenile Myositis
-
批准号:10683016
-
项目类别:
-
资助金额:$23.14万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Charcot-Marie-Tooth (CMT) Disease
-
批准号:10263802
-
项目类别:
-
资助金额:$7.02万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Assays to evaluate biological pathways in Parkinsons disease
-
批准号:10469249
-
项目类别:
-
资助金额:$22.95万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Charcot-Marie-Tooth (CMT) Disease
-
批准号:10469248
-
项目类别:
-
资助金额:$6.66万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Phenotypic Assay Design and Development for Rare and Neglected Diseases
-
批准号:10469250
-
项目类别:
-
资助金额:$51.34万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Pharmacological Modulation of Parkin Expression and Function to Attenuate Mitochondrial Dysfunction
-
批准号:9354990
-
项目类别:
-
资助金额:$6.3万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery
-
批准号:10683014
-
项目类别:
-
资助金额:$45.05万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Juvenile Myositis
-
批准号:9551939
-
项目类别:
-
资助金额:$15.63万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Charcot-Marie-Tooth (CMT) Disease
-
批准号:10907359
-
项目类别:
-
资助金额:$13.87万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Assays to evaluate biological pathways in Parkinsons disease
-
批准号:10907360
-
项目类别:
-
资助金额:$13.87万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery
-
批准号:10907362
-
项目类别:
-
资助金额:$69.33万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase
-
批准号:10919689
-
项目类别:
-
资助金额:$27.73万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Charcot-Marie-Tooth (CMT) Disease
-
批准号:10007534
-
项目类别:
-
资助金额:$6.33万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Alpha-1 antitrypsin (AAT) deficiency
-
批准号:10007533
-
项目类别:
-
资助金额:$6.52万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Peroxisome biogenesis disorders (PBDs)
-
批准号:10263807
-
项目类别:
-
资助金额:$21.04万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
C. elegans as a model organism for human disease through the application of phenologs
-
批准号:10469264
-
项目类别:
-
资助金额:$16.44万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery
-
批准号:9551433
-
项目类别:
-
资助金额:$36.66万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
SARS CoV-2 Nsp1 inhibitor
-
批准号:10263809
-
项目类别:
-
资助金额:$22.11万
-
财政年份:--
-
负责人:James Inglese
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: